Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    86,380.15
    +667.18 (+0.78%)
     

  • CMC Crypto 200

    1,311.55
    +34.57 (+2.71%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

New Strong Buy Stocks for July 20th

Tirthankar Chakraborty
Updated

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Agenus Inc (AGEN): This immuno-oncology (I-O) company has witnessed the Zacks Consensus Estimate for its current year earnings surging 10.2% over the last 30 days.

Agenus Inc. Price and Consensus

 

Agenus Inc. Price and Consensus | Agenus Inc. Quote

Alcobra Ltd (ADHD): This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings soaring 16.7% over the last 30 days.

Alcobra Ltd. Price and Consensus

 

Alcobra Ltd. Price and Consensus | Alcobra Ltd. Quote

BOK Financial Corporation (BOKF): This financial holding company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 30 days.

ADVERTISEMENT

BOK Financial Corporation Price and Consensus

 

BOK Financial Corporation Price and Consensus | BOK Financial Corporation Quote

Cellectis SA (CLLS): This company active in the field of genome engineering and genomic surgery has seen the Zacks Consensus Estimate for its current year earnings increasing 2.9% over the last 30 days.

Cellectis S.A. Price and Consensus

 

Cellectis S.A. Price and Consensus | Cellectis S.A. Quote

Chemours Co (CC): This provider of performance chemicals has witnessed the Zacks Consensus Estimate for its current year earnings improving 4.5% over the last 30 days.

Chemours Company (The) Price and Consensus

 

Chemours Company (The) Price and Consensus | Chemours Company (The) Quote

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

Want to see all of today's Zacks Strong Buys?                                                     

You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 stocks free of charge. There is no better place to start your own stock search. Plus you can also access the full list of must-avoid Zacks Strong Sells and other private research. See the stocks free >>.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cellectis S.A. (CLLS) : Free Stock Analysis Report
 
Chemours Company (The) (CC) : Free Stock Analysis Report
 
BOK Financial Corporation (BOKF) : Free Stock Analysis Report
 
Agenus Inc. (AGEN) : Free Stock Analysis Report
 
Alcobra Ltd. (ADHD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research